ArticleEuropean journal of human genetics : EJHG2026
Prevalence and penetrance of heritable retinoblastoma in two adult population cohorts: implications for genomic newborn screening.
Article in European journal of human genetics : EJHG, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
Retinoblastoma (Rb) is a rare childhood eye cancer. Almost half of cases are heritable, associated with germline RB1 pathogenic variants that pre-dispose to Rb and extraocular cancers. This study aimed to investigate the prevalence and penetrance of RB1-heritable Rb in two adult population cohorts. We screened participants with whole genome sequencing in the UK Biobank (UKB) (n = 490,413) and All of Us (AoU) (n = 317,964) cohorts for predicted loss-of-function (pLoF) and/or ClinVar pathogenic/likely pathogenic RB1 variants. Electronic health records and questionnaires were used to screen participants for Rb-associated features. In the UKB we generated a stringent and permissive phenotype category, ranging from Rb to Rb-associated extraocular cancers; in AoU we included participants with Rb or ocular cancer. A total of 21 pathogenic pLoF RB1 variants were detected in the UKB (n = 12) and AoU (n = 13) participants. In the UKB, only 25.0% (3/12) of variant carriers reported developing Rb by the age of 60, increasing to 50.0% when including ocular/extraocular cancers. Similarly, 30.8% (4/13) AoU participants developed Rb and/or ocular cancer by the age of 60. Overall, this results in a combined penetrance estimate of 28.0% (7/25). We found 21 and 28 individuals with Rb in the UKB and AoU, respectively, which is consistent with published prevalence estimates, suggesting these cohorts are not depleted of Rb cases. Notably, the penetrance of pathogenic RB1 variants in >800,000 clinically unselected adults was substantially lower than the near complete penetrance reported in clinical cohorts. This has important implications for counselling families following a positive newborn screening result.
Identifiers
42760334What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.